EUVIMEDEUVIMED entdecken
Crossref

ROS-sensitive nanocarriers for synergistic X-PDT/chemo/immunotherapy of triple-negative breast cancer and metastasis

Chaorong Wei, Lingke Feng, Jing Liu, Mingxia Xu, Yongsheng Cui, Fengyi Lin, Honglian Yu, Zhanzhan Feng, Hong Zhang, Changyang Gong, Peng Mi

Acta Biomaterialia · 2026-01 · 210 · 441-456

DOI: 10.1016/j.actbio.2025.12.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-01. Verfasst von Chaorong Wei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Huaxi MR Research Center (HMRRC), State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17 South R…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Photochemotherapy, Immunotherapy, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, West China Hospital, Sichuan University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

X-ray-induced photodynamic therapy (X-PDT) shows significant promise in tumor treatments due to its unlimited tissue penetration but requires delivering sensitizers to tumors. Here, we engineered photosensitizer verteporfin (VP) and T-lymphokine-activated killer cell-originated protein kinase (TOPK) inhibitor OTS964-encapsulated polymeric nanocarriers (VP/OTS964@NPs) for effective tumor X-PDT, molecule-targeted therapy and inducing robust antitumor immunity for synergistic immunotherapy of low immunogenic breast tumors and their lung metastases when combined with PD-L1 blockade. The VP/OTS964@NPs are monodisperse and can be disassembled to release drugs in response to high reactive oxygen species (ROS) levels in the tumor microenvironment or generated during X-PDT. It can efficiently deliver drugs into the TOPK-high expression breast cancer cells, generate ROS and induce ICD effects. By i.v. injection, VP/OTS964@NPs efficiently accumulated in the breast tumors and effectively eradicated tumors upon X-PDT. Additionally, the VP/OTS964@NPs activated the systemic antitumor immune responses, significantly inhibited the distant breast tumors and the lung metastasis of breast tumors, and enhanced the survival rates in combination with PD-L1 blockade. This study presented a strategy for engineering nanocarriers for synergistic molecular therapy, tumor XDT and immunotherapy. STATEMENT OF SIGNIFICANCE: X-PDT is a promising therapeutic modality for cancer treatment. However, its clinical application is hindered by the limited availability of suitable sensitizers and their insufficient tumor-targeting capability. This work aims to construct ROS-sensitive nanocarriers co-loaded with the photosensitizer verteporfin and the TOPK inhibitor OTS964 to achieve synergistic X-PDT for triple-negative breast cancer. By further activating antitumor immune responses, this strategy is designed to suppress the distant and metastatic breast tumors. Overall, this work provides both a nanodrug platform and a therapeutic strategy for the treatment of poorly immunogenic solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reactive Oxygen SpeciesPhotochemotherapyImmunotherapyTriple Negative Breast NeoplasmsNanoparticlesDrug CarriersLung NeoplasmsHumansAnimalsFemaleCell Line, TumorVerteporfinMice, Inbred BALB CMicePhotosensitizing AgentsNeoplasm MetastasisMice, Nude

Stichwörter der Autor:innen

CancerImmunotherapyNanocarriersROSStimuli-responsiveTOPKX-PDT

Substanzen

Reactive Oxygen SpeciesDrug CarriersVerteporfinPhotosensitizing Agents

Autor:innen und Institutionen

  • Department of Radiology, Huaxi MR Research Center (HMRRC), State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17 South Renmin Road, Chengdu, Sichuan, 610041, China.
  • Department of Radiology, Huaxi MR Research Center (HMRRC), State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17 South Renmin Road, Chengdu, Sichuan, 610041, China. Electronic address: ljing…
  • Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
  • Hospital of Chengdu University of Traditional Chinese Medicine, 37 Shi-er-qiao Road, Jinniu District, Chengdu, Sichuan, 610075, China.
  • Department of Radiology, Huaxi MR Research Center (HMRRC), State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, No.17 South Renmin Road, Chengdu, Sichuan, 610041, China; College of Polymer Scienc…

Förderung

  • China Postdoctoral Science Foundation
  • West China Hospital, Sichuan University
  • National Natural Science Foundation of China

Zitieren

APA

Wei, C., Feng, L., Liu, J., Xu, M., Cui, Y., Lin, F., Yu, H., Feng, Z., Zhang, H., Gong, C., & Mi, P. (2026). ROS-sensitive nanocarriers for synergistic X-PDT/chemo/immunotherapy of triple-negative breast cancer and metastasis. Acta Biomaterialia, 210, 441-456. https://doi.org/10.1016/j.actbio.2025.12.035

Vancouver

Wei C, Feng L, Liu J, Xu M, Cui Y, Lin F, et al. ROS-sensitive nanocarriers for synergistic X-PDT/chemo/immunotherapy of triple-negative breast cancer and metastasis. Acta Biomaterialia. 2026;210:441-456. doi:10.1016/j.actbio.2025.12.035

BibTeX
@article{Wei2026,
  author = {Wei, Chaorong and Feng, Lingke and Liu, Jing and Xu, Mingxia and Cui, Yongsheng and Lin, Fengyi and Yu, Honglian and Feng, Zhanzhan and Zhang, Hong and Gong, Changyang and Mi, Peng},
  title = {ROS-sensitive nanocarriers for synergistic X-PDT/chemo/immunotherapy of triple-negative breast cancer and metastasis},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {210},
  pages = {441--456},
  doi = {10.1016/j.actbio.2025.12.035}
}
Kostenlos starten →